Matthew R Brier1, Jewell B Thomas2, Abraham Z Snyder2, Liang Wang2, Anne M Fagan2, Tammie Benzinger2, John C Morris2, Beau M Ances2. 1. From the Program in Neuroscience, Division of Biological and Biomedical Science (M.R.B.), and Departments of Neurology (J.B.T., A.Z.S., L.W., A.M.F., J.C.M., B.M.A.) and Radiology (A.Z.S., T.B., B.M.A.), School of Medicine, Washington University in St. Louis; and Hope Center for Neurological Disorders (A.M.F., T.B., B.M.A.), Knight Alzheimer's Disease Research Center (A.M.F., T.B., J.C.M., B.M.A.), and Department of Biomedical Engineering (B.M.A.), Washington University in St. Louis, MO. brierm@wusm.wustl.edu. 2. From the Program in Neuroscience, Division of Biological and Biomedical Science (M.R.B.), and Departments of Neurology (J.B.T., A.Z.S., L.W., A.M.F., J.C.M., B.M.A.) and Radiology (A.Z.S., T.B., B.M.A.), School of Medicine, Washington University in St. Louis; and Hope Center for Neurological Disorders (A.M.F., T.B., B.M.A.), Knight Alzheimer's Disease Research Center (A.M.F., T.B., J.C.M., B.M.A.), and Department of Biomedical Engineering (B.M.A.), Washington University in St. Louis, MO.
Abstract
OBJECTIVE: To determine whether, and to what degree, preclinical Alzheimer disease (AD) confounds studies of healthy aging where "healthy" is based on cognitive normality alone. METHODS: We examined the effects of preclinical AD in cognitively normal older individuals using resting-state functional connectivity MRI. We investigated 2 groups of cognitively normal participants: one group with evidence of preclinical AD as assessed by CSF markers of AD and the other group with normal CSF biomarkers. RESULTS: There were significant interactions between age and biomarker status in the default-mode, dorsal attention, and salience resting-state networks. In the group with evidence of preclinical AD, there were dramatic changes in functional connectivity with age. In the group without evidence of preclinical AD, those changes were greatly attenuated. In most regions with significant interactions of age and biomarker status, the age-related change in functional connectivity in the normal biomarker group was indistinguishable from zero. CONCLUSIONS: These results suggest that preclinical AD accounts for a substantial portion of the reported effects of aging in the extant functional connectivity literature.
OBJECTIVE: To determine whether, and to what degree, preclinical Alzheimer disease (AD) confounds studies of healthy aging where "healthy" is based on cognitive normality alone. METHODS: We examined the effects of preclinical AD in cognitively normal older individuals using resting-state functional connectivity MRI. We investigated 2 groups of cognitively normal participants: one group with evidence of preclinical AD as assessed by CSF markers of AD and the other group with normal CSF biomarkers. RESULTS: There were significant interactions between age and biomarker status in the default-mode, dorsal attention, and salience resting-state networks. In the group with evidence of preclinical AD, there were dramatic changes in functional connectivity with age. In the group without evidence of preclinical AD, those changes were greatly attenuated. In most regions with significant interactions of age and biomarker status, the age-related change in functional connectivity in the normal biomarker group was indistinguishable from zero. CONCLUSIONS: These results suggest that preclinical AD accounts for a substantial portion of the reported effects of aging in the extant functional connectivity literature.
Authors: E T Bullmore; J Suckling; S Overmeyer; S Rabe-Hesketh; E Taylor; M J Brammer Journal: IEEE Trans Med Imaging Date: 1999-01 Impact factor: 10.048
Authors: Bruce Fischl; David H Salat; André J W van der Kouwe; Nikos Makris; Florent Ségonne; Brian T Quinn; Anders M Dale Journal: Neuroimage Date: 2004 Impact factor: 6.556
Authors: D S Knopman; J E Parisi; A Salviati; M Floriach-Robert; B F Boeve; R J Ivnik; G E Smith; D W Dickson; K A Johnson; L E Petersen; W C McDonald; H Braak; R C Petersen Journal: J Neuropathol Exp Neurol Date: 2003-11 Impact factor: 3.685
Authors: Jessica R Andrews-Hanna; Abraham Z Snyder; Justin L Vincent; Cindy Lustig; Denise Head; Marcus E Raichle; Randy L Buckner Journal: Neuron Date: 2007-12-06 Impact factor: 17.173
Authors: Ammar H Hawasli; Jerrel Rutlin; Jarod L Roland; Rory K J Murphy; Sheng-Kwei Song; Eric C Leuthardt; Joshua S Shimony; Wilson Z Ray Journal: J Neurotrauma Date: 2018-01-11 Impact factor: 5.269
Authors: Peter R Millar; Beau M Ances; Brian A Gordon; Tammie L S Benzinger; Anne M Fagan; John C Morris; David A Balota Journal: Neurobiol Aging Date: 2020-08-18 Impact factor: 4.673
Authors: Jasmeer P Chhatwal; Aaron P Schultz; Keith A Johnson; Trey Hedden; Sehily Jaimes; Tammie L S Benzinger; Clifford Jack; Beau M Ances; John M Ringman; Daniel S Marcus; Bernardino Ghetti; Martin R Farlow; Adrian Danek; Johannes Levin; Igor Yakushev; Christoph Laske; Robert A Koeppe; Douglas R Galasko; Chengjie Xiong; Colin L Masters; Peter R Schofield; Kirsi M Kinnunen; Stephen Salloway; Ralph N Martins; Eric McDade; Nigel J Cairns; Virginia D Buckles; John C Morris; Randall Bateman; Reisa A Sperling Journal: Brain Date: 2018-05-01 Impact factor: 13.501
Authors: S Duke Han; Patricia A Boyle; Lei Yu; Konstantinos Arfanakis; Bryan D James; Debra A Fleischman; David A Bennett Journal: Brain Imaging Behav Date: 2016-06 Impact factor: 3.978